Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions
This article was originally published in The Tan Sheet
Executive SummaryAdams Respiratory Therapeutics' net sales grew 11 percent to $84 million in its latest quarter as sales of single-ingredient Mucinex were cannibalized by newer extensions in the product line
You may also be interested in...
In addition to CBD, Elixicure is formulated with OTC external analgesics monograph ingredients camphor and menthol, But CBD isn't a monograph drug nor approved for use in any pharmaceutical product other than GW Pharmaceutical's Epidiolex.
In addition proposing $28.4m in monograph user fees, agency’s FY 2021 budget justification includes among its legislative initiatives proposing to require "Field Alert Reports" for drug products not marketed under an approved application, such as monograph OTCs.